Literature DB >> 28452165

Cutaneous Toxicities From Transplantation-Related Medications.

M Ilyas1, O R Colegio2, B Kaplan3, A Sharma1.   

Abstract

Despite the abundance of information on cutaneous malignancies associated with solid organ transplantation in the transplant literature, there is limited information regarding nonmalignant skin changes after transplantation. There are numerous skin toxicities secondary to immunosuppressive and other transplant-related medications that can vary in presentation, severity, and prognosis. To limit associated morbidity and mortality, solid organ transplant recipient care providers should effectively identify and manage cutaneous manifestations secondary to drug toxicity. Toxicities from the following transplant-related medications will be discussed: antithymocyte globulins, systemic steroids, cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mammalian target of rapamycin inhibitors sirolimus and everolimus, basiliximab and daclizumab, belatacept, and voriconazole.
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research/practice; complication; dermatology; drug toxicity; health services and outcomes research; immunosuppressant; immunosuppression/immune modulation; pharmacology

Mesh:

Substances:

Year:  2017        PMID: 28452165     DOI: 10.1111/ajt.14337

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  2 in total

Review 1.  Dermatological Complications After Solid Organ Transplantation.

Authors:  Luigi Naldi; Anna Venturuzzo; Pietro Invernizzi
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

2.  Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.

Authors:  Anastasia Martynova; Victor Chiu; Melissa Mert; David Hermel; Ilene Ceil Weitz
Journal:  Ann Hematol       Date:  2021-01-09       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.